Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guobo Li

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Diabetes, Obesity & Metabolism|May 31, 2026
Unveiling the BMI Risk Threshold for Osteoarthritis: Multi-Database Causal and Nonlinear EvidenceShaohong Yu, Li Zeng, Lei Yang, et al.
BMC Pediatrics|November 14, 2023
Exploring the association between circRNA expression and pediatric obesity based on a case-control study and related bioinformatics analysisGuobo Li, Xingyan Xu, Le Yang, et al.
Frontiers in Immunology|April 29, 2025
Combination of Sodium Butyrate and Immunotherapy in Glioma: regulation of immunologically hot and cold tumors via gut microbiota and metabolitesSui Li, Li Wang, MingYu Han, et al.
European Journal of Medicinal Chemistry|April 18, 2017
Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitorsLingling Yang, Xiaobo Ma, Chen Yuan, et al.
International Journal of Environmental Research and Public Health|October 27, 2022
Physical Changes of Preschool Children during COVID-19 School Closures in Fujian, ChinaGuobo Li, Le Yang, Xingyan Xu, et al.
British Journal of Pharmacology|April 19, 2013
YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical modelsYouzhi Xu, Hongjun Lin, Nana Meng, et al.
BMC Cancer|July 19, 2015
A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activitiesYouzhi Xu, Wenjie Lu, Peng Yang, et al.
Journal of Medicinal Chemistry|July 28, 2015
Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and EfficaciesTao Yang, Gong Chen, Zitai Sang, et al.
Acta Pharmaceutica Sinica. B|April 3, 2025
Enhanced BBB penetration and microglia-targeting nanomodulator for the two-pronged modulation of chronically activated microglia-mediated neuroinflammation in Alzheimer's diseaseYa Wei, Xue Xia, Xiaorong Wang, et al.
Journal of Medicinal Chemistry|April 20, 2026
Correction to "Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence"Kun Zhang, Yuhan Lin, Ling Dong, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|May 31, 2026
Unveiling the BMI Risk Threshold for Osteoarthritis: Multi-Database Causal and Nonlinear EvidenceShaohong Yu, Li Zeng, Lei Yang, et al.
BMC Pediatrics|November 14, 2023
Exploring the association between circRNA expression and pediatric obesity based on a case-control study and related bioinformatics analysisGuobo Li, Xingyan Xu, Le Yang, et al.
Frontiers in Immunology|April 29, 2025
Combination of Sodium Butyrate and Immunotherapy in Glioma: regulation of immunologically hot and cold tumors via gut microbiota and metabolitesSui Li, Li Wang, MingYu Han, et al.
European Journal of Medicinal Chemistry|April 18, 2017
Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitorsLingling Yang, Xiaobo Ma, Chen Yuan, et al.
International Journal of Environmental Research and Public Health|October 27, 2022
Physical Changes of Preschool Children during COVID-19 School Closures in Fujian, ChinaGuobo Li, Le Yang, Xingyan Xu, et al.
British Journal of Pharmacology|April 19, 2013
YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical modelsYouzhi Xu, Hongjun Lin, Nana Meng, et al.
BMC Cancer|July 19, 2015
A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activitiesYouzhi Xu, Wenjie Lu, Peng Yang, et al.
Journal of Medicinal Chemistry|July 28, 2015
Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and EfficaciesTao Yang, Gong Chen, Zitai Sang, et al.
Acta Pharmaceutica Sinica. B|April 3, 2025
Enhanced BBB penetration and microglia-targeting nanomodulator for the two-pronged modulation of chronically activated microglia-mediated neuroinflammation in Alzheimer's diseaseYa Wei, Xue Xia, Xiaorong Wang, et al.
Journal of Medicinal Chemistry|April 20, 2026
Correction to "Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence"Kun Zhang, Yuhan Lin, Ling Dong, et al.
Pageof 5